Emerging Biopharmaceutical Markets to Witness Exponential Growth Document Transcript
Emerging Biopharmaceutical Markets to Witness ExponentialGrowthIMARC Group, one of the world‘s leading research and advisory firms, finds that the sales ofBiopharmaceuticals in Emerging markets will nearly triple its size from US$ 5.3 Billion in 2010 toUS$ 13.5 Billion in 2015IMARC Group, one of the world‘s leading research and advisory firms, finds in its new report“Global Biopharmaceutical Market Report & Forecast 2010-2015” that driven by a huge patient pool,rapid economic growth and improving intellectual property rights, the sales of biopharmaceuticals in the sevenemerging markets - Russia, China, Turkey, Mexico, South Korea, India and Brazil will nearly triple from thecurrent US$ 5.3 Billion to more than US$ 13.6 billion by 2015.As per the research findings, the treatment costs associated with biopharmaceuticals are extremely high and attimes can exceed hundreds of thousands of dollars a year. Since most of the healthcare costs in the emergingmarkets are paid out-of-pocket, most patients cannot afford these treatments. However, the seven emergingmarkets taken together account for more than three billion people, representing more than 45% of the totalGlobal population. So even if a small percentage of patients are able to afford these drugs, it still represents ahuge market potential. Moreover, the GDPs of emerging markets have witnessed strong growth during the lastfew years, and this is likely to continue in the coming years as well. This is expected to create a huge middleclass that can afford innovative treatments.The report also suggests that despite the huge opportunity, these markets will not be easy for westernmanufacturers to penetrate. A major challenge for manufacturers entering these markets is the fact thatemerging markets are more complex and different from the developed markets as well as from each other. Astrategy that will work in Turkey will not work well in India or China. Manufacturers will have to devisestrategies, customized as per the requirements of the individual markets.IMARC’s new report “Global Biopharmaceutical Market Report 2010-2015” gives a deep insight into theglobal biopharmaceutical market. The research study serves as an analytical as well as a statistical tool tounderstand the strengths, weaknesses, opportunities, threats, market trends, geographical structure,therapeutic structure, competitive structure and the outlook of the global biopharmaceutical market till 2015.This report can serve as an excellent guide for investors, researchers, consultants, marketing strategists, andall those who are planning to foray into the global biopharmaceutical market in some form or the other.
Report Highlights: Biopharmaceuticals enjoy a higher approval success rate compared to traditional small molecule drugs. They, however, require higher investments and take longer development times. Biopharmaceuticals are significantly more expensive than traditional medications, with the annual cost of therapy of some biopharmaceuticals touching more than a hundred thousand dollars a year. The cost of these drugs, however, is expected to be closely scrutinized by payers in the coming years. Recombinant Proteins represented the biggest biopharmaceutical class in 2009, accounting for more than 65% of the total global biopharmaceutical sales. Growth in this class is expected to be low in most of the developed markets as a result of biosimilar entry and increasing cost containment measures. Monoclonal Antibodies are expected to be the biggest drivers of the biopharmaceutical market in the next five years. Driven by a rich late stage pipeline and a strong uptake from both developed and emerging market, Monoclonal Antibodies are expected to be worth more than US$ 79 Billion by 2015. Imarc expects the top eight markets (US, Germany, Japan, France, Italy, Spain, UK and Canada) to account for around 79% of the total global biopharmaceutical sales by 2015. This represents a decline of 4% over their 2009 share. The market share of emerging markets (Brazil, Russia, India, China, Mexico, Turkey and South Korea) is likely to increase from less than 5% in 2009 to more than 8% by 2015.Countries CoveredGlobal, US, Germany, Japan, France, Italy, Spain, United Kingdom, Canada, Russia, China, Australia, Turkey,Mexico, South Korea, India, Brazil, Argentina and Indonesia.Classes Covered for Each Region/CountryRecombinant Proteins, Insulin, Erythropoietins, Interferons, Colony Stimulating Factors, Immunoglobulins,Recombinant Blood Factors, Growth Hormones, Recombinant Enzymes, Interleukins, Growth Factors,Monoclonal Antibodies and Purified Proteins.Key Features Analysis of the key strengths, weaknesses, opportunities and threats faced by the global biopharmaceutical market. Exhaustive in-depth individual analysis for eighteen major developed and emerging markets. 2005 to 2009 trend analysis for the global and 18 selected biopharmaceutical markets.
2005 to 2009 trend analysis for individual biopharmaceutical classes for the global and 18 selected biopharmaceutical markets. 2005 to 2009 trend analysis for the performance of top players for the global and 18 selected biopharmaceutical markets.Table of Contents1. Market Definitions & Research Methodology2. Analyst Briefing3. Introduction to Biopharmaceuticals4. Global Biopharmaceutical Market: Industry Analysis4.1 Strengths4.1.1 High Efficacy and Target Oriented Attack4.1.2 Strong Potential to Achieve Blockbuster Status4.1.3 Limited Generic Threat4.1.4 Approval Success Rates are Higher than Small Molecule Drugs4.2 Weaknesses4.2.1 Inconvenient Drug Delivery Coupled with Short Half Lives4.2.2 Second Line of Therapy4.2.3 Huge Cost of Therapy4.2.4 High Incidence of Unfavorable Side Effects4.3 Opportunities4.3.1 Diseases with High Unmet Needs4.3.2 Expanding the Patient Pool by Approval into Additional Indications4.3.3 Emerging Markets4.3.4 Increasing New Approvals and a Strong Pipeline4.4 Threats4.4.1 Biopharmaceutical Drug Development is a Very Risky Venture4.4.2 Biosimilars4.4.3 Limited and Conditional Reimbursement4.4.4 Uncertainties in the Economic Environment
5. Global Biopharmaceutical Market: Industry Performance5.1 Market Performance & Forecast5.1.1 Current Performance (2005-2009)5.1.2 Market Forecasts (2010-2015)5.2 Market Segmentation by Region5.2.1 Current Performance (2005-2009)5.2.2 Market Forecasts (2010-2015)5.3 Market Segmentation by Indication5.4 Market Segmentation by Class5.4.1 Recombinant Proteins5.4.2 Monoclonal Antibodies5.4.3 Purified Proteins5.5 Competitive Landscape5.5.1 Top Biopharmaceutical Players5.5.2 Top Biopharmaceutical Drugs6. North America6.1 US6.1.1 Market Performance (2005-2009)6.1.2 Market Segmentation by Class6.1.3 Performance of Top Players6.1.4 Market Forecasts (2010-2015)6.2 Canada6.2.1 Market Performance (2005-2009)6.2.2 Market Segmentation by Class6.2.3 Performance of Top Players6.2.4 Market Forecasts (2010-2015)7. Latin America7.1 Mexico7.1.1 Market Performance (2005-2009)7.1.2 Market Segmentation by Class
7.1.3 Performance of Top Players7.1.4 Market Forecasts (2010-2015)7.2 Brazil7.2.1 Market Performance (2005-2009)7.2.2 Market Segmentation by Class7.2.3 Performance of Top Players7.2.4 Market Forecasts (2010-2015)7.3 Argentina7.3.1 Market Performance (2005-2009)7.3.2 Market Segmentation by Class7.3.3 Performance of Top Players7.3.4 Market Forecasts (2010-2015)8. Europe8.1 Germany8.1.1 Market Performance (2005-2009)8.1.2 Market Segmentation by Class8.1.3 Performance of Top Players8.1.4 Market Forecasts (2010-2015)8.2 France8.2.1 Market Performance (2005-2009)8.2.2 Market Segmentation by Class8.2.3 Performance of Top Players8.2.4 Market Forecasts (2010-2015)8.3 Italy8.3.1 Market Performance (2005-2009)8.3.2 Market Segmentation by Class8.3.3 Performance of Top Players8.3.4 Market Forecasts (2010-2015)8.4 Spain8.4.1 Market Performance (2005-2009)
8.4.2 Market Segmentation by Class8.4.3 Performance of Top Players8.4.4 Market Forecasts (2010-2015)8.5 UK8.5.1 Market Performance (2005-2009)8.5.2 Market Segmentation by Class8.5.3 Performance of Top Players8.5.4 Market Forecasts (2010-2015)8.6 Russia8.6.1 Market Performance (2005-2009)8.6.2 Market Segmentation by Class8.6.3 Performance of Top Players8.6.4 Market Forecasts (2010-2015)8.7 Turkey8.7.1 Market Performance (2005-2009)8.7.2 Market Segmentation by Class8.7.3 Performance of Top Players8.7.4 Market Forecasts (2010-2015)9. Asia Pacific9.1 Japan9.1.1 Market Performance (2005-2009)9.1.2 Market Segmentation by Class9.1.3 Performance of Top Players9.1.4 Market Forecasts (2010-2015)9.2 China9.2.1 Market Performance (2005-2009)9.2.2 Market Segmentation by Class9.2.3 Performance of Top Players9.2.4 Market Forecasts (2010-2015)9.3 Australia
9.3.1 Market Performance (2005-2009) 9.3.2 Market Segmentation by Class 9.3.3 Performance of Top Players 9.3.4 Market Forecasts (2010-2015) 9.4 South Korea 9.4.1 Market Performance (2005-2009) 9.4.2 Market Segmentation by Class 9.4.3 Performance of Top Players 9.4.4 Market Forecasts (2010-2015) 9.5 India 9.5.1 Market Performance (2005-2009) 9.5.2 Market Segmentation by Class11 9.5.3 Performance of Top Players 9.5.4 Market Forecasts (2010-2015) 9.6 Indonesia 9.6.1 Market Performance (2005-2009) 9.6.2 Market Segmentation by Class 9.6.3 Performance of Top Players 9.6.4 Market Forecasts (2010-2015) To buy the complete report or to get a free sample, please contact:IMARC Group AsiaEmail: email@example.comPhone: +91-120-425-6531IMARC Group North AmericaEmail: firstname.lastname@example.orgPhone: +1-631-791-1145IMARC Group Europe, Middle East & AfricaEmail:email@example.comPhone: +44-702-409-7331To know more please visit: http://www.imarcgroup.com/global-biopharmaceutical-market-report-2010-2015/